Pencil Biosciences

Pencil Biosciences is an early-stage biotech developing a novel, synthetic RNA-guided gene editing platform positioned as an alternative to CRISPR-based systems. Its core innovation is a 'break-free' editing mechanism that avoids creating double-strand DNA breaks, potentially reducing off-target effects and expanding editable genomic sites. The company, which is privately held and pre-revenue, has secured initial grant and venture funding to advance its platform towards therapeutic applications in oncology and genetic diseases. Leadership is bolstered by recent appointments including an experienced Chair of the Board.

A fully synthetic, modular, RNA-guided gene editing platform that performs 'break-free' editing without causing DNA double-strand breaks or nicks. Described as non-CRISPR in nature, small, and flexible.

Operates in the highly competitive next-generation gene editing space, competing against well-funded companies improving CRISPR (e.g., Beam, Prime Medicine) and developing alternative systems. Must differentiate on safety (break-free editing), precision, and targeting flexibility to capture market share.